Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma
PURPOSE For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 s...
Gespeichert in:
| Veröffentlicht in: | Clinical nuclear medicine 2002-11, Vol.27 (11), p.781-784 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 784 |
|---|---|
| container_issue | 11 |
| container_start_page | 781 |
| container_title | Clinical nuclear medicine |
| container_volume | 27 |
| creator | HELLWIG, DIRK SAMNICK, SAMUEL REIF, JOHANNES ROMEIKE, BERND F.M REITH, WOLFGANG MORINGLANE, JEAN R KIRSCH, CARL-MARTIN |
| description | PURPOSE For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.
MATERIALS AND METHODS The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.
RESULTS Although the tumor-to-background ratios were higher for the In-111–labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m–labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope.
CONCLUSIONS SPECT with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas. |
| doi_str_mv | 10.1097/00003072-200211000-00005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72513664</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72513664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3865-b42e480371f2d329c68eb87d153109ff151789b64598063d309e525342a588983</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxS1URJfCV6h8oTeDx_9iH9G2hUqtKqFytrzOpA0k9tZOVPHtm2W39MRcrHn6vRn7mRAK_DNw13zhS0neCCY4FwBLx3aSfkNWoKVhXAh3RFZcGslcY8QxeV_rL87BgFHvyDEI6RQItSI36zxuQ-lrTjR39C4y50Z6jtuCeepbpCG19CoxAKC3cXpR-0R_YJxLwTTRG0x9uu_zGD6Qt10YKn48nCfk5-XF3fo7u779drX-es2itEazjRKoLJcNdKKVwkVjcWObdrn78ryuAw2NdRujtLPcyFZyh1poqUTQ1jorT8jZfu625McZ6-THvkYchpAwz9U3QoM0Ri2g3YOx5FoLdn5b-jGUPx6430XpX6L0_6L8K-nFenrYMW9GbF-Nh-wW4NMBCDWGoSshxb6-ctJZrcRukNpzT3mYsNTfw_yExT9gGKYH_7-vlM9SKob_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72513664</pqid></control><display><type>article</type><title>Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>HELLWIG, DIRK ; SAMNICK, SAMUEL ; REIF, JOHANNES ; ROMEIKE, BERND F.M ; REITH, WOLFGANG ; MORINGLANE, JEAN R ; KIRSCH, CARL-MARTIN</creator><creatorcontrib>HELLWIG, DIRK ; SAMNICK, SAMUEL ; REIF, JOHANNES ; ROMEIKE, BERND F.M ; REITH, WOLFGANG ; MORINGLANE, JEAN R ; KIRSCH, CARL-MARTIN</creatorcontrib><description>PURPOSE For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.
MATERIALS AND METHODS The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.
RESULTS Although the tumor-to-background ratios were higher for the In-111–labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m–labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope.
CONCLUSIONS SPECT with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas.</description><identifier>ISSN: 0363-9762</identifier><identifier>EISSN: 1536-0229</identifier><identifier>DOI: 10.1097/00003072-200211000-00005</identifier><identifier>PMID: 12394124</identifier><identifier>CODEN: CNMEDK</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott Williams & Wilkins, Inc</publisher><subject>Biological and medical sciences ; Eye Neoplasms - diagnostic imaging ; Eye Neoplasms - surgery ; Female ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Medical sciences ; Meningeal Neoplasms - diagnostic imaging ; Meningeal Neoplasms - surgery ; Meningioma - diagnostic imaging ; Meningioma - surgery ; Middle Aged ; Neoplasm Recurrence, Local - diagnostic imaging ; Nervous system ; Neurology ; Octreotide - analogs & derivatives ; Organotechnetium Compounds ; Radionuclide Imaging ; Radionuclide investigations ; Radiopharmaceuticals ; Somatostatin - analogs & derivatives ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Clinical nuclear medicine, 2002-11, Vol.27 (11), p.781-784</ispartof><rights>2002 Lippincott Williams & Wilkins, Inc.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3865-b42e480371f2d329c68eb87d153109ff151789b64598063d309e525342a588983</citedby><cites>FETCH-LOGICAL-c3865-b42e480371f2d329c68eb87d153109ff151789b64598063d309e525342a588983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13985425$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12394124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HELLWIG, DIRK</creatorcontrib><creatorcontrib>SAMNICK, SAMUEL</creatorcontrib><creatorcontrib>REIF, JOHANNES</creatorcontrib><creatorcontrib>ROMEIKE, BERND F.M</creatorcontrib><creatorcontrib>REITH, WOLFGANG</creatorcontrib><creatorcontrib>MORINGLANE, JEAN R</creatorcontrib><creatorcontrib>KIRSCH, CARL-MARTIN</creatorcontrib><title>Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma</title><title>Clinical nuclear medicine</title><addtitle>Clin Nucl Med</addtitle><description>PURPOSE For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.
MATERIALS AND METHODS The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.
RESULTS Although the tumor-to-background ratios were higher for the In-111–labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m–labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope.
CONCLUSIONS SPECT with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas.</description><subject>Biological and medical sciences</subject><subject>Eye Neoplasms - diagnostic imaging</subject><subject>Eye Neoplasms - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Medical sciences</subject><subject>Meningeal Neoplasms - diagnostic imaging</subject><subject>Meningeal Neoplasms - surgery</subject><subject>Meningioma - diagnostic imaging</subject><subject>Meningioma - surgery</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Octreotide - analogs & derivatives</subject><subject>Organotechnetium Compounds</subject><subject>Radionuclide Imaging</subject><subject>Radionuclide investigations</subject><subject>Radiopharmaceuticals</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0363-9762</issn><issn>1536-0229</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU9v1DAQxS1URJfCV6h8oTeDx_9iH9G2hUqtKqFytrzOpA0k9tZOVPHtm2W39MRcrHn6vRn7mRAK_DNw13zhS0neCCY4FwBLx3aSfkNWoKVhXAh3RFZcGslcY8QxeV_rL87BgFHvyDEI6RQItSI36zxuQ-lrTjR39C4y50Z6jtuCeepbpCG19CoxAKC3cXpR-0R_YJxLwTTRG0x9uu_zGD6Qt10YKn48nCfk5-XF3fo7u779drX-es2itEazjRKoLJcNdKKVwkVjcWObdrn78ryuAw2NdRujtLPcyFZyh1poqUTQ1jorT8jZfu625McZ6-THvkYchpAwz9U3QoM0Ri2g3YOx5FoLdn5b-jGUPx6430XpX6L0_6L8K-nFenrYMW9GbF-Nh-wW4NMBCDWGoSshxb6-ctJZrcRukNpzT3mYsNTfw_yExT9gGKYH_7-vlM9SKob_</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>HELLWIG, DIRK</creator><creator>SAMNICK, SAMUEL</creator><creator>REIF, JOHANNES</creator><creator>ROMEIKE, BERND F.M</creator><creator>REITH, WOLFGANG</creator><creator>MORINGLANE, JEAN R</creator><creator>KIRSCH, CARL-MARTIN</creator><general>Lippincott Williams & Wilkins, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200211</creationdate><title>Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma</title><author>HELLWIG, DIRK ; SAMNICK, SAMUEL ; REIF, JOHANNES ; ROMEIKE, BERND F.M ; REITH, WOLFGANG ; MORINGLANE, JEAN R ; KIRSCH, CARL-MARTIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3865-b42e480371f2d329c68eb87d153109ff151789b64598063d309e525342a588983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Eye Neoplasms - diagnostic imaging</topic><topic>Eye Neoplasms - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Medical sciences</topic><topic>Meningeal Neoplasms - diagnostic imaging</topic><topic>Meningeal Neoplasms - surgery</topic><topic>Meningioma - diagnostic imaging</topic><topic>Meningioma - surgery</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Octreotide - analogs & derivatives</topic><topic>Organotechnetium Compounds</topic><topic>Radionuclide Imaging</topic><topic>Radionuclide investigations</topic><topic>Radiopharmaceuticals</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HELLWIG, DIRK</creatorcontrib><creatorcontrib>SAMNICK, SAMUEL</creatorcontrib><creatorcontrib>REIF, JOHANNES</creatorcontrib><creatorcontrib>ROMEIKE, BERND F.M</creatorcontrib><creatorcontrib>REITH, WOLFGANG</creatorcontrib><creatorcontrib>MORINGLANE, JEAN R</creatorcontrib><creatorcontrib>KIRSCH, CARL-MARTIN</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HELLWIG, DIRK</au><au>SAMNICK, SAMUEL</au><au>REIF, JOHANNES</au><au>ROMEIKE, BERND F.M</au><au>REITH, WOLFGANG</au><au>MORINGLANE, JEAN R</au><au>KIRSCH, CARL-MARTIN</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma</atitle><jtitle>Clinical nuclear medicine</jtitle><addtitle>Clin Nucl Med</addtitle><date>2002-11</date><risdate>2002</risdate><volume>27</volume><issue>11</issue><spage>781</spage><epage>784</epage><pages>781-784</pages><issn>0363-9762</issn><eissn>1536-0229</eissn><coden>CNMEDK</coden><abstract>PURPOSE For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.
MATERIALS AND METHODS The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.
RESULTS Although the tumor-to-background ratios were higher for the In-111–labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m–labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope.
CONCLUSIONS SPECT with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>12394124</pmid><doi>10.1097/00003072-200211000-00005</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9762 |
| ispartof | Clinical nuclear medicine, 2002-11, Vol.27 (11), p.781-784 |
| issn | 0363-9762 1536-0229 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72513664 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Biological and medical sciences Eye Neoplasms - diagnostic imaging Eye Neoplasms - surgery Female Humans Investigative techniques, diagnostic techniques (general aspects) Medical sciences Meningeal Neoplasms - diagnostic imaging Meningeal Neoplasms - surgery Meningioma - diagnostic imaging Meningioma - surgery Middle Aged Neoplasm Recurrence, Local - diagnostic imaging Nervous system Neurology Octreotide - analogs & derivatives Organotechnetium Compounds Radionuclide Imaging Radionuclide investigations Radiopharmaceuticals Somatostatin - analogs & derivatives Tumors of the nervous system. Phacomatoses |
| title | Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A08%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Tc-99m%20Depreotide%20and%20In-111%20Octreotide%20in%20Recurrent%20Meningioma&rft.jtitle=Clinical%20nuclear%20medicine&rft.au=HELLWIG,%20DIRK&rft.date=2002-11&rft.volume=27&rft.issue=11&rft.spage=781&rft.epage=784&rft.pages=781-784&rft.issn=0363-9762&rft.eissn=1536-0229&rft.coden=CNMEDK&rft_id=info:doi/10.1097/00003072-200211000-00005&rft_dat=%3Cproquest_cross%3E72513664%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72513664&rft_id=info:pmid/12394124&rfr_iscdi=true |